Millions of stroke survivors across the world may soon have a new defense
The therapy -- Ryoncil (remestemcel-L-rknd) -- will be tested in adults with severe steroid-refractory acute graft-versus-host disease
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
The partnership combines Croda’s deep expertise in smart science and global market reach with Amino’s advanced capabilities in precision manufacturing of amino acids
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
Subscribe To Our Newsletter & Stay Updated